07:00 , Apr 4, 2016 |  BioCentury  |  Emerging Company Profile

Sugar-coated bugs

Centauri Therapeutics Ltd .'s alphamer technology recruits a population of pre-existing, endogenous polyclonal antibodies to kill antibiotic-resistant bacteria. Centauri acquired the technology from Altermune Technologies LLC , a company founded by PCR inventor Kary Mullis....
07:00 , May 28, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Galactose-α-1,3-galactosyl-β-1,4-N

Infectious disease INDICATION: Bacterial infection In vitro studies suggest bacterial-targeted conjugates of DNA aptamers and α-GAL (alphamers) could help treat bacterial infections. In co-cultures of Streptococci and human or mouse anti-α-GAL antibodies, an alphamer containing...
07:00 , May 28, 2015 |  BC Innovations  |  Product R&D

Altermune's Alphamers

Altermune Technologies LLC is taking immunotherapy back to its day job of fighting infections with a new technology that coats bacteria with a sugar, and recruits circulating antibodies against the sugar to find and destroy...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Financial News

Altermune Technologies completes venture financing

Altermune Technologies LLC   Business: Infectious   Date completed: 9/22/11   Type: Venture financing   Raised: $7 million   Investor: Loxbridge Research   Note: The newco named Kary Mullis as its chief scientific officer.  ...
00:25 , Sep 23, 2011 |  BC Extra  |  Company News

Altermune launches with Mullis as CSO

Kary Mullis, the Nobel Prize winning inventor of PCR, and VC firm Loxbridge Research formed Altermune Technologies LLC (Orange County, Calif.) to develop therapeutics for drug-resistant pathogens. Loxbridge will provide up to $7 million in...